Laurion Capital Management’s Theseus Pharmaceuticals, Inc. Common Stock THRX Stock Holding History

Laurion Capital Management’s Portfolio THRX Stock Details THRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-130,945	Closed	-$530K	–	662
2023 Q4	$530K	Sell	130,945 -40,212	-23%	-$123K	﹤0.01%	388
2023 Q3	$460K	Sell	171,157 -8,462	-5%	-$33.2K	﹤0.01%	397
2023 Q2	$1.68M	Hold	179,619	–	–	0.01%	325
2023 Q1	$1.6M	Hold	179,619	–	–	0.01%	284
2022 Q4	$895K	Hold	179,619	–	–	﹤0.01%	338
2022 Q3	$1.04M	Hold	179,619	–	–	0.01%	367
2022 Q2	$994K	Hold	179,619	–	–	0.02%	282
2022 Q1	$2.07M	Sell	179,619 -25,402	-12%	-$272K	0.03%	209
2021 Q4	$2.6M	Buy	+205,021	New	+$3.1M	0.03%	246

Laurion Capital Management's THRX Position: Q1 2024 in Review

Laurion Capital Management sold out of Theseus Pharmaceuticals, Inc. Common Stock (THRX) in Q1 2024, closing a stake of 130,945 shares — an estimated $530K sold.

Laurion Capital Management first reported a position in THRX in Q4 2021 and held it in 9 quarters. The position peaked at $2.6M in Q4 2021. 1 fund tracked by Wall St. Rank holds THRX as of Q1 2024.

Laurion Capital Management reported no remaining Theseus Pharmaceuticals, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Laurion Capital Management sold 130,945 Theseus Pharmaceuticals, Inc. Common Stock shares in Q1 2024, an estimated $530K.
Laurion Capital Management first reported a position in Theseus Pharmaceuticals, Inc. Common Stock in Q4 2021 and held it in 9 quarters.
Laurion Capital Management's Theseus Pharmaceuticals, Inc. Common Stock position peaked at $2.6M in Q4 2021.
1 fund tracked by Wall St. Rank held Theseus Pharmaceuticals, Inc. Common Stock as of Q1 2024.

Based on Laurion Capital Management's 13F filing for Q1 2024, filed 15 May 2024.